Recipharm Appoints New Directors, Business Management to Further Strengthen European Sales Drive
Recipharm has appointed two new Directors of Business Management. These appointments form part of Recipharm’s strategic drive to increase the volume of its business and revenues in key European markets.
Henning Neubauer has joined the Business Management team at Recipharm, taking on the position of Business Director for Northern Germany and the Netherlands. In parallel, Antonio Lopez also joins the team in the role of Business Director for Spain and Southern France.
Previously, Neubauer was Chief Operating Officer (COO) at a German start-up company in Hamburg dealing with generic products, OTC and Rx. Prior to that, he worked for more than 10 years at Haupt Pharma as Head of Customer Service and Sales, responsible for leading the Customer Service Team and key account management. He has a degree and Diploma in Marketing from the Open University of Bad Harzburg.
Antonio Lopez, has previous experiences in Business Development and partnering, logistics, compliance and regulatory activities in the role as VP of Operations in Flavine, a US trading company involved in generics APIs and finished dosage forms. Prior to this, he worked for more than 20 years at the Spanish pharmaceutical company Grupo Uriach. Antonio graduated with a Pharmacist degree from the University of Barcelona and holds a Masters in Business Administration from Barcelona’s Esade Business School.
As a further initiative to bolster the Business Management organisation, Åsa Wilander joined the team in mid-January in the new role of Key Account Director for the Nordic region. In this role, Åsa will be responsible for co-ordinating customer management and commercial aspects, as well as developing relationships with a selected number of customers. Åsa has been with Recipharm since 2007. To date, she has been working as General Manager of the Höganäs facility and led a significant expansion of the company. She has some 30 years experience of the pharmaceutical industry including the leadership of a contract manufacturing supply team at Pfizer.
Commenting on the new appointments, Kenth Berg, VP Business Management Recipharm, stated: “I am very pleased to have such talent join our business management structure. Europe is one of our key markets and we look forward to utilising the respective skills and expertise of Henning and Antonio to further enhance our European sales drive in Germany, the Netherlands and Spain.”
He continued: “Indeed post our recent IPO, this is an exciting time to plan ahead and expand our revenues and turnover across our international operations of which Europe is a highly important component”.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance